Status: Not yet recruiting
A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
A study of the efficacy and safety of VSA012 Injection compared to eculizumab for 24 weeks in patients with PNH.
Participants needed: 70
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Bisirna Therapeutics (Suzhou) Co., Ltd.Updated: Sep 11, 2026Locations: 14
Eligibility criteria
Male and female participants ≥ 18 years of age and BMI ≥ 18.0 kg/m2 with a diagn... [+5]
Known or suspected hereditary or acquired complement deficiency; [+7]